The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.
 
Toshiaki Iwase
No Relationships to Disclose
 
Senthil Damodaran
Consulting or Advisory Role - AstraZeneca; Taiho Oncology
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); DualityBio (Inst); EMD Serono (Inst); Guardant Health (Inst); MediLink Therapeutics (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
 
Angela Marx
No Relationships to Disclose
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Calibr; Daiichi Sankyo/Astra Zeneca; EcoR1 Capital; Eisai; Exelixis; GT Aperion; Incyte; Infinity Pharmaceuticals; Karyopharm Therapeutics; LegoChem Biosciences; Lengo Therapeutics; Menarini Group; OnCusp Therapeutics; Protai; Seagen; Tallac Therapeutics; Theratechnologies; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARTIDIS; Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Debashish Tripathy
Consulting or Advisory Role - Ambrx; AstraZeneca; Genomic Health; Gilead Sciences; GlaxoSmithKline; Menarini; Novartis; OncoPep; Personalis; Pfizer; Roche; Sermonix Pharmaceuticals
Research Funding - Ambrx (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Carlos Hernando Barcenas
Research Funding - Puma Biotechnology (Inst)
 
Jangsoon Lee
Consulting or Advisory Role - Astrion
Research Funding - Daiichi Sankyo; OBI Pharma
 
Naoto Tada Ueno
Stock and Other Ownership Interests - Pear Bio
Honoraria - Anheart Therapeutics; Bayer; Bristol-Myers Squibb/Celgene; Carna Biosciences; Chugai/Roche; CytoDyn; Daiichi Sankyo; Genomic Health; Kyowa Hakko Kirin; Kyowa Kirin International; Medscape; Medsir; Pfizer; Pfizer; Phoenix Molecular Designs; Sumitomo Dainippon Pharma Oncology; Sysmex
Consulting or Advisory Role - Anheart Therapeutics; Bayer; Bristol-Myers Squibb/Celgene; Carna Biosciences; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Phoenix Molecular Designs; Preferred Medicine; Sysmex
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; CytoDyn; Daiichi Sankyo; Duality Biologics; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Preferred Medicine; Puma Biotechnology; Sysmex